Haematology-Oncology · Clinical trials
Multiple Myeloma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About multiple myeloma — and why its trials are hard
Multiple myeloma is a malignancy of clonal plasma cells in the bone marrow, producing monoclonal immunoglobulin (M-protein) and causing the CRAB features: hypercalcaemia, renal impairment, anaemia and lytic bone lesions. It remains incurable but survival has transformed over two decades through sequential classes of therapy. Immunomodulatory drugs (lenalidomide) and proteasome inhibitors (bortezomib, carfilzomib) became backbone agents, and the anti-CD38 antibody daratumumab, validated in CASTOR, POLLUX and MAIA, added deep, durable responses across relapsed and frontline transplant-ineligible settings. Treatment is typically layered: induction with triplet/quadruplet regimens, autologous stem-cell transplant in eligible patients, and maintenance. For heavily pre-treated, triple-class-exposed disease, BCMA-directed therapies now dominate: CAR-T cells (idecabtagene vicleucel, ciltacabtagene autoleucel) and the bispecific antibody teclistamab produce unprecedented response rates. Minimal residual disease (MRD) negativity is an increasingly important depth-of-response endpoint. Despite progress, essentially all patients eventually relapse, driving continued trial activity.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Lenalidomide (Revlimid) | 2006 | Relapsed/refractory (with dexamethasone); later frontline and maintenance | MM-009 / MM-010 | Time to progression / PFS | TTP roughly 11 vs 5 months with lenalidomide-dexamethasone vs dexamethasone |
| Bortezomib (Velcade) | 2003 | Relapsed/refractory, later frontline induction | APEX | Time to progression / overall survival | TTP ~6.2 vs 3.5 months vs high-dose dexamethasone; OS benefit |
| Daratumumab (Darzalex) | 2015 (monotherapy); 2016 combinations; 2019 frontline transplant-ineligible | Relapsed and newly diagnosed | CASTOR (Dara-Vd), POLLUX (Dara-Rd), MAIA (Dara-Rd frontline) | Progression-free survival | CASTOR PFS HR ~0.39; POLLUX HR ~0.37; MAIA HR ~0.56 with OS benefit |
| Carfilzomib (Kyprolis) | 2012 | Relapsed/refractory | ASPIRE (with lenalidomide-dexamethasone) | Progression-free survival | PFS ~26.3 vs 17.6 months vs Rd |
| Ciltacabtagene autoleucel (Carvykti) | 2022 | Relapsed/refractory (later lines; 2024 expanded to earlier relapse) | CARTITUDE-1 (CARTITUDE-4 for earlier lines) | Overall response rate / PFS | ORR ~98% in heavily pre-treated patients; deep durable responses |
| Teclistamab (Tecvayli) | 2022 | Triple-class-exposed relapsed/refractory | MajesTEC-1 | Overall response rate | BCMAxCD3 bispecific; ORR ~63% (off-the-shelf) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in multiple myeloma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Venetoclax — BELLINI (with bortezomib-dexamethasone) | PFS improved but overall survival was worse in the venetoclax arm due to excess infection-related deaths | Increased mortality in the unselected population; benefit is confined to the t(11;14)/BCL2-high subgroup, so it remains investigational/off-label rather than broadly approved |
Choosing the right endpoint
Primary endpoints that matter in multiple myeloma trials
- Progression-free survival (PFS) — Primary efficacy endpoint in most pivotal myeloma trials
- Overall survival (OS) — Gold standard but requires long follow-up; confounded by effective subsequent therapies
- Overall response rate (ORR) — Includes partial response or better per IMWG criteria; key for single-arm relapsed trials
- MRD negativity — Deep-response biomarker (e.g. 10^-5); increasingly used and prognostic
- Complete response / VGPR rate — Depth-of-response measures correlating with durability
How iNGENū runs multiple myeloma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Multiple Myeloma clinical trials — FAQs
Is multiple myeloma curable?
What is the role of stem-cell transplant?
What are BCMA-targeted therapies?
Ready to discuss your multiple myeloma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal